- $19.98m
- $10.71m
- $57.57m
Brief: Aytu Biopharma - AR101 Granted Orphan Designation In Europe For Treatment Of Ehlers-Danlos Syndrome
Aytu Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Brief: Aytu Biopharma Inc - Quarterly Net Revenue Increased 53% Year-Over-Year To $23.1 Million
Aytu Biopharma Inc expected to post a loss of 58 cents a share - Earnings Preview
Brief: Aytu Biopharma Inc - Aytu Biopharma Appoints Mark Oki As Chief Financial Officer
Brief: Denovo Biopharma Llc Announces Partner Aytu Biopharma Receives FDA Clearance For Enzastaurin
U.S. STOCKS ON THE MOVE-Novavax, Harley-Davidson, Peloton, Arena Pharma
Aytu rises as FDA clears clinical trial application for rare genetic therapy
Brief: Aytu Biopharma Announces FDA Clearance Of IND Application For AR101/Enzastaurin In Vascular Ehlers-Danlos Syndrome
Brief: Aytu Biopharma - On December 8, 2021, Richard Eisenstadt Resigned As CFO, Effective December 30
Aytu Biopharma Inc reports results for the quarter ended in September - Earnings Summary
Brief: Aytu Biopharma Reports Q1 Loss Per Share Of $1.09
Aytu Biopharma Inc expected to post a loss of 49 cents a share - Earnings Preview
Aytu Biopharma Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Aytu Biopharma Inc Files For Mixed Shelf Of Upto $100 Million
Brief: Aytu Biopharma Says Quarterly Net Revenue Increased 74% Sequentially To $23.5 Million
Aytu Biopharma Inc reports results for the quarter ended in June - Earnings Summary
Aytu Biopharma Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Aytu Biopharma Says Signed Asset Purchase Agreement With UAB Caerus Biotechnologies